Newly Diagnosed Aplastic Anemia, Refractory Aplastic Anemia, Severe Aplastic Anemia
Conditions
Keywords
JAK1 inhibitor, Intensive immunosuppressive therapy
Brief summary
This study is designed as a Phase Ib/II trial. The phase Ib cohort will enroll patients with severe aplastic anemia (SAA) who have failed to respond to intensified immunosuppressive therapy. In contrast, the phase II cohort will include newly diagnosed and treatment-naïve patients with SAA. A Safety Review Committee (SRC), chaired by the principal investigators, will be established to oversee patient safety throughout the study. Suppose the Phase Ib results demonstrate acceptable safety and tolerability. In that case, the data will be submitted to the Ethics Committee for review, and, upon approval, the study will advance to Phase II. Phase Ib uses a 3+3 dose-escalation design with two cohorts: 150 mg golidocitinib orally every other day (low dose) or once daily (high dose). Phase II is a single-arm trial with Simon's two-stage optimal design.
Interventions
DRUGGolidocitinib Capsules
In phase Ib, the low-dose cohort will receive golidocitinib 150 mg orally every other day (qod), and the high-dose cohort will receive golidocitinib 150 mg orally once daily (qd).
Sponsors
Institute of Hematology & Blood Diseases Hospital, China
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Phase Ib: Inclusion Criteria: * According to the Chinese Guidelines for the Diagnosis and Treatment of Aplastic Anemia (2022 Edition) and the Guidelines for the diagnosis and management of adult aplastic anaemia: A British Society for Haematology Guideline (Br J Haematol. 2024; 204: 784-804), the patient is diagnosed with primary acquired AA and meets the diagnostic criteria for SAA. * Subjects received intensive immunosuppressive therapy combined with a standard-dose TPO receptor agonist for at least 4 months but failed to respond or experienced relapse. * Unsuitable for or unwilling to undergo allogeneic hematopoietic stem cell transplantation and lacking other superior treatment options. * Age ≥ 18 years * ECOG performance status ≤2 * Willing and able to comply with the requirements for this study and written informed consent.
Exclusion criteria
* Presence of any other primary or secondary bone marrow failure syndrome, including but not limited to Fanconi anemia, myelodysplastic syndrome (MDS), clonal cytopenia of undetermined significance, or large granular lymphocytic leukemia. * Bone marrow reticulin fibrosis ≥ grade 2 * Subjects with a paroxysmal nocturnal hemoglobinuria (PNH) clone ≥ 50% or with evidence of active hemolysis. * Presence of clonal cytogenetic abnormalities characteristic of MDS, excluding +8, del(20q), and -Y. * Active infection within 2 weeks before first dosing of the investigational product, including bacterial, viral, or fungal infections (common cold and onychomycosis excluded). Any anti-infective treatment must be completed at least 2 weeks before dosing. History of HIV infection or HIV antibody positive at screening. Positive treponemal antibody for syphilis at screening. Active pulmonary tuberculosis, defined as evidence of active TB on chest imaging or other relevant assessments within 3 months before first dosing or during screening. Active hepatitis at screening, defined as: HBsAg positivity; or HBcAb positivity with HBV DNA ≥ 30 IU/mL; or HCV antibody positivity with detectable HCV RNA. * Active bleeding involving the gastrointestinal tract, respiratory tract, central nervous system, or other sites. * History of clinically significant diseases that, in the investigator's judgment, may pose a risk to the participant's safety if enrolled in the study, or may interfere with the assessment of efficacy or safety during the study, including but not limited to: 1. Cardiovascular diseases: history within the past year of acute myocardial infarction or unstable angina, severe arrhythmias (e.g., frequent multifocal ventricular premature beats, ventricular tachycardia, ventricular fibrillation), congestive heart failure, arterial or venous thrombosis, or New York Heart Association (NYHA) class III-IV heart failure. 2. History of psychiatric disorders or presence of severe cerebrovascular disease or cognitive sequelae. * Treatment with mycophenolate mofetil, tacrolimus, sirolimus, cyclophosphamide, anti-CD52 monoclonal antibody, or other similar therapies within 4 weeks or 5 half-lives of the first dose of the investigational product, whichever is shorter. * Planned participation in another clinical trial, or prior exposure to investigational products in another clinical trial within 4 weeks or within 5 half-lives of the first dose of the investigational product, whichever is shorter. * Received a live attenuated vaccine within 4 weeks before the first dose of the investigational product, planned administration of a live attenuated vaccine during the study, or received a COVID-19 vaccine within 7 days before dosing. * Prior treatment with a JAK inhibitor. * Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study; female participants of childbearing potential and male participants whose partners are of childbearing potential who do not agree to use highly effective contraception throughout the study period (from signing the ICF until 6 months after the last dose of the investigational product), or those planning to donate oocytes or sperm during the study. * Subjects that the investigator believes have other reasons that make them unsuitable for inclusion in this study. Phase II: Inclusion Criteria: * According to the Chinese Guidelines for the Diagnosis and Treatment of Aplastic Anemia (2022 Edition) and the Guidelines for the diagnosis and management of adult aplastic anaemia: A British Society for Haematology Guideline (Br J Haematol. 2024; 204: 784-804), the patient is diagnosed with primary acquired AA and meets the diagnostic criteria for SAA. * Meets the diagnostic criteria for severe aplastic anemia (Br J Haematol. 2024; 204: 784-804), which require: 1. Bone marrow cellularity less than 25% of normal; if ≥ 25% but \< 50%, residual hematopoietic cells must be \< 30%. 2. Peripheral blood counts must meet at least two of the following three criteria: Absolute neutrophil count (ANC) \< 0.5 × 10\^9/L, Absolute reticulocyte count \< 60 × 10\^9/L, Platelet count (PLT) \< 20 × 10\^9/L * Unsuitable for or unwilling to undergo allogeneic hematopoietic stem cell transplantation. * Age ≥ 18 years * ECOG performance status ≤2 * Willing and able to comply with the requirements for this study and written informed consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence and severity of adverse events | Within 12 weeks | This primary outcome measure applies to Phase Ib, and adverse events will be assessed using the Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. |
| Percentage of patients with complete hematological response | Within 3 months post treatment | This primary outcome measure applies to Phase II, and a complete hematological response (CR) is defined as meeting all of the following criteria: 1) HGB ≥ 100 g/L; 2) PLT ≥ 100 × 10\^9/L; 3) ANC ≥ 1.0 × 10\^9/L. |
Contacts
Primary ContactLele Zhang, PhD
Outcome results
None listed